PDCD1 and cancer: Trial-level subgroup sizes varied across cancer types.<h4>Conclusions</h4>Adjuvant PD-1 and PD-L1 inhibitors improve disease-free and distant metastasis-free survival in selected patients with high-risk solid tumors.